

Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Crenessity (crinecerfont) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 6 months; Continuation- 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Crenessity (crinecerfont)** for **Commercial, Exchange, FEHB (Federal),** and **MD Medicaid** plans. Please complete all sections, incomplete forms will delay processing. Fax this form back to Kaiser Permanente within 24 hours fax: <u>1-866-331-2104</u>. If you have any questions or concerns, please call <u>1-866-331-2103</u>. Requests will not be considered unless this form is complete. The KP-MAS Formulary can be found at: Pharmacy

Community Provider Portal | Kaiser Permanente

1 – Patient Information		
Patient Name:	Kaiser Medical ID#:	Date of Birth:
	2 – Provider Information	
Provider Name:	Specialty:	NPI:
Provider Address:		
Provider Phone #:	Provider Fax #:	
Do you have an approved provider referral number from Kaiser Permanente? □ Yes – please provide your provider referral number here:		
3 – Pharmacy Information		
Pharmacy Name:	Pharmacy NPI:	
Pharmacy Phone #	Pharmacy Fax #:	
	4 – Drug Therapy Requested	
Drug 1: Name/Strength/Formu	ulation:	
Drug 2: Name/Strength/Formu	ulation:	
Sig:		
	5– Diagnosis/Clinical Criteria	
1. Is this request for initial or		
☐ Initial therapy	☐ Continuing therapy, state start date:	
2. Indicate the patient's diagnosis for the requested medication:		

	Clinical Criteria: 1. Is this medication being prescribed by an Endocrinologist or Pediatric Endrocinologist? □ No □ Yes		
2.	. Is the patient ≥4 years of age? □ No □ Yes		
3.	Does the patient have a diagnosis of 21-hydroxylase deficiency CAH (classic congenital adrenal hyperplasia) confirmed by at least ONE of the following? ○ Elevated 17-hydroxyprogesterone level ○ Confirmed CYP21A2 gene mutation ○ Positive newborn screening with confirmatory second-tier testing (e.g., serum testing for 17-hydroxyprogesterone and cortisol levels; serum electrolytes) ○ Cosyntropin (ACTH) stimulation test		
4.	. Is the patient currently taking a systemic glucocorticoid (e.g., hydrocortisone, prednisone, prednisolone, dexamethasone), AND will continue glucocorticoid therapy in combination with Crenessity? □ No □ Yes		
For continuation of therapy, please respond to <u>additional questions</u> below. New members who were initiated on therapy			
	tside of Kaiser, who have not been reviewed previously, must meet all above Clinical Criteria. Does the patient continue to be under the care of an Endocrinologist or Pediatric Endocrinologist, and has had follow-up since last review? □ No □ Yes		
2.	 Is there documentation of clinical benefit from therapy, as evidenced by disease stability or improvement (e.g., decreased androstenedione or 17-hydroxyprogesterone levels; reduction in required glucocorticoid dose from baseline; decrease in body mass index standard deviation scores; improved insulin resistance; reduction in hirsutism; improvement in androstenedione-to-testosterone ratio) No Yes 		
	6 – Provider Sign-Off		
Additional Information – 1. Please submit chart notes/medical records for the patient that are applicable to this request. 2. If member has not tried preferred agent(s) please provide rationale/explanation and any additional supporting information that should be taken into consideration for the requested medication:			
I certify that the information provided is accurate. Supporting documentation is available for State audits.			
	ovider Signature: Date:		
Plea	ise Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is		

private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility